Strategic acquisitions DCR expanded capabilities through the 2022 MedSleuth acquisition, signaling a growth trajectory and potential cross-sell opportunities to clients seeking broader clinical data services and enhanced trial management.

Clinical trial footprint With involvement in over 500 clinical trials across more than 175 pharmaceutical companies, DCR demonstrates extensive experience and reliability that can be leveraged to win new Phase II-III study engagements from sponsors seeking proven CRO partnerships.

Kidney care heritage As a DaVita subsidiary with roots in kidney care, DCR can target sponsors prioritizing nephrology and related multi-specialty trials, offering specialized site networks and patient recruitment channels relevant to renal indications.

Strategic alliances Past collaborations such as the Quintiles partnership indicate a history of successful alliances; this track record positions DCR as a credible partner for co-development models or alliance-based trial programs.

Digital and compliance readiness Utilizing tools like OneTrust, Sucuri, WordPress and Marketo, DCR demonstrates solid compliance, security and marketing automation capabilities, enabling scalable outreach, risk management and efficient site enrollment communications.